Anebulo Pharmaceuticals to Present at Upcoming Investor and Scientific Conferences

Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced that it will be giving an investor presentation at the H.C. Wainwright 25th Annual Global Investment Conference, from September 11 to September 13. In addition, the Company announced the acceptance of three presentations at two upcoming scientific conferences, the North American Congress on Clinical Toxicology, taking place in Montreal, from September 29 to October 1, and the American Congress of Emergency Physicians, taking place in Philadelphia from October 9 to October 12. The two oral presentations will focus on data from Parts A and B of the Phase 2 study and the poster will present modeling of ANEB-001 doses for ACI.

Details for the upcoming conference presentations are as follows:

H.C. Wainwright 25th Annual Global Investment Conference (New York, September 11 – September 13)

• The Company presentation will be available on-demand on September 11, 2023, at 7 a.m. ET through the conference website.
• Simon Allen, Chief Executive Officer of Anebulo, will be available in person for one-on-one investor meetings.

North American Congress on Clinical Toxicology (Montreal, September 29 – October 1)

• Oral Presentation Title: Randomized Controlled Trial of ANEB-001 as an Antidote for Acute Cannabinoid Intoxication in Healthy Adults
• Presenter: Andrew Monte, MD, Ph.D.
• Date: Friday, September 29, 2023, from 1 p.m. to 3 p.m. ET

American Congress of Emergency Physicians (Philadelphia, October 9 – 12)

• Poster Presentation Title: Prediction of a Therapeutically Active Dose of the Cannabinoid Type 1 Receptor Antagonist ANEB-001 For Reversal of Acute Cannabis Intoxication Using a Pharmacokinetic / Pharmacodynamic Model
• Presenter: Linda Klumpers, Ph.D.
• Date: Monday, October 9, 2023, at 10:30 a.m. ET
• Location: Room 108AB
• Oral Presentation Title: Randomized Controlled Trial of ANEB-001 as an Antidote for Acute Cannabinoid Intoxication in Healthy Adults
• Presenter: Andrew Monte, MD, Ph.D.
• Date: Tuesday, October 10, 2023, at 3:30 p.m. ET
• Location: Room 105AB

About the Phase 2 study of ANEB-001